Parabilis Posts Q2 Loss of $2.32/Share, $1.1B Cash, and Regeneron Collaboration Details
PBLS sits 53% above its 52-week low of $24.51 on light trading volume (0.3× avg).
Summary
Parabilis Medicines reported a Q2 net loss of $52.5 million with $1.1 billion in cash, and provided detailed updates on its Regeneron collaboration and clinical pipeline.
Key Events · Earnings and Guidance · PBLS
-
Q2 Net Loss of $52.5M
The net loss widened to $52.5 million for Q2 2026, up from $34.8 million a year earlier, driven by higher R&D and G&A expenses.
-
Cash Position of $1.1B
Cash, cash equivalents, and marketable securities totaled $1.1 billion as of June 30, 2026, a balance expected to fund operations into 2030.
-
Regeneron Collaboration Terms
Under the collaboration, Parabilis received $125 million in upfront and equity investment from Regeneron, with potential for up to $2.2 billion in milestone payments plus royalties.
-
Phase 3 Desmoid Trial Planned
The company expects to engage with the FDA in Q4 2026 and initiate a Phase 3 registrational trial for zolucatetide in desmoid tumors in 1H 2027.
Analysis · PBLS · Life Sciences
In its first quarterly report since the June IPO, Parabilis Medicines recorded a net loss of $52.5 million for Q2 2026. The company closed the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, a runway it expects to fund operations into 2030. The filing also outlines the Regeneron collaboration, which includes $125 million in upfront and equity investment and up to $2.2 billion in potential milestones. On the clinical front, a Phase 3 trial for zolucatetide in desmoid tumors is planned for the first half of 2027, with FDA engagement set for Q4 2026.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBLS was trading at $37.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $24.51 to $37.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.